Advancing Biopharmaceutical Innovation with Creative Capital Solutions

HealthCare Royalty is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products.

Royalty Monetization

EXPLORE

Corporate Financing

EXPLORE

$5B+

Invested in more than 85 biopharma products since inception

$5B+

Invested in more than 85 biopharma products since inception and offices in NY Metro Area, CA, MA and UK

NY

New York Metro Area

CA

San Francisco

MA

Boston

UK

London

34

34

Team members

MEET OUR TEAM

Interview with Neil McFarlane, Former CEO, Adamas Pharmaceuticals

Interview with Gary Lyons, HCRx Senior Advisor

Interview with Dennis Lanfear, President, CEO and Chairman, Coherus BioSciences

Interview with Dr. Greg Went, Former Chairman & CEO, Adamas Pharmaceuticals (December 2017)

Interview with Julie McHugh, HCRx Senior Advisor

Interview with Julie Anne Smith, Former President and CEO, Raptor Pharmaceuticals

Interview with Dr. Robert Langer, HCRx Senior Advisor

Interview with Mardi Dier, Former CFO, Portola, HCRx Board Member

Interview with Marc Kozin, HCRx Board Member

Interview with Nat Ricciardi, HCRx Senior Advisor

Spotlight
Latest News

Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty

HealthCare Royalty Announces Closing of Credit Facility, New Debt Focused Fund and Appointment of Josh House as West Coast Lead

TheracosBio Announces Royalty Financing Agreement with HealthCare Royalty

Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

uniQure Announces Sale of Royalty Interest in HEMGENIX ® for Up To $400 Million

More News